These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36241853)

  • 1. A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge.
    Leen-Feldner EW; Bynion TM; Eglit GML; Bonn-Miller MO; Gournay LR; Feldner MT
    Psychopharmacology (Berl); 2022 Oct; ():. PubMed ID: 36241853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cannabidiol-rich hemp extract oil on reconsolidation disruption of naturalistic interoceptive aversive memory in humans: Protocol for a randomized clinical trial.
    Zaizar ED; Papini S; O'Connor P; Telch MJ
    Contemp Clin Trials; 2022 Aug; 119():106847. PubMed ID: 35811050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
    van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
    BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students.
    Stanley TB; Ferretti ML; Bonn-Miller MO; Irons JG
    Cannabis Cannabinoid Res; 2023 Dec; 8(6):1090-1099. PubMed ID: 35861792
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
    Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
    Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.
    Kwee CM; Baas JM; van der Flier FE; Groenink L; Duits P; Eikelenboom M; van der Veen DC; Moerbeek M; Batelaan NM; van Balkom AJ; Cath DC
    Eur Neuropsychopharmacol; 2022 Jun; 59():58-67. PubMed ID: 35561538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.
    Gournay LR; Ferretti ML; Bilsky S; Vance E; Nguyen AM; Mann E; Williams P; Leen-Feldner EW
    Psychopharmacology (Berl); 2023 Oct; 240(10):2147-2161. PubMed ID: 37552290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial.
    Telch MJ; Fischer CM; Zaizar ED; Rubin M; Papini S
    Contemp Clin Trials; 2022 Nov; 122():106933. PubMed ID: 36154908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study.
    Zhekova RM; Perry RN; Spinella TC; Dockrill K; Stewart SH; Barrett SP
    J Psychopharmacol; 2024 Jan; 38(1):116-124. PubMed ID: 38214314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
    Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
    Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol enhances consolidation of explicit fear extinction in humans.
    Das RK; Kamboj SK; Ramadas M; Yogan K; Gupta V; Redman E; Curran HV; Morgan CJ
    Psychopharmacology (Berl); 2013 Apr; 226(4):781-92. PubMed ID: 23307069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Crippa JAS; Pacheco JC; Zuardi AW; Guimarães FS; Campos AC; Osório FL; Loureiro SR; Dos Santos RG; Souza JDS; Ushirohira JM; Ferreira RR; Mancini Costa KC; Scomparin DS; Scarante FF; Pires-Dos-Santos I; Mechoulam R; Kapczinski F; Fonseca BAL; Esposito DLA; Passos ADC; Dal Fabbro AL; Bellissimo-Rodrigues F; Arruda E; Scarpelini S; Andraus MH; Nather Junior JC; Wada DT; Koenigkam-Santos M; Santos AC; Busatto Filho G; Hallak JEC
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):658-669. PubMed ID: 34619044
    [No Abstract]   [Full Text] [Related]  

  • 17. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
    Hurd YL; Spriggs S; Alishayev J; Winkel G; Gurgov K; Kudrich C; Oprescu AM; Salsitz E
    Am J Psychiatry; 2019 Nov; 176(11):911-922. PubMed ID: 31109198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
    Dixon T; Cadenhead KS
    Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.